Comparable stake leader
Affinity Asset Advisors, LLC
SEC ownership of iBio, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001420720.
Disclosed value leader
Sirenia Capital Management LP
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Symbol
- IBIO on Nasdaq
- Ownership evidence mix
- 13D/G and 13F
- Largest current holder
- Affinity Asset Advisors, LLC
- Latest large-stake holder
- Affinity Asset Advisors, LLC
- Latest evidence date
- 31 Mar 2026
- CIK
- 0001420720
- Location
- New York, NY
Ownership snapshot
2 signals
Issuer identity
2 identity fields
Ownership snapshot
Top shareholders of iBio, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Affinity Asset Advisors, LLC
Disclosed value leader
Sirenia Capital Managemen...
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
13F
Lead comparable stake: 10%
13D/G row: Affinity Asset Advisors, LLC
Showing 1-8 of 50 holder rows.
Quick read
Affinity Asset Advisors, LLC leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
Affinity Asset Advisors, LLC
10%
Adage Capital Management, L.P.
10%
SILVERARC CAPITAL MANAGEMENT, LLC
10%
Cormorant Asset Management, LP
10%
Sirenia Capital Management LP
9.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC |
13D/G
13F
Company
|
10%
|
$7,675,906
3,489,048 shares
|
+$2,392,350 | 31 Mar 2026 |
| Adage Capital Management, L.P. |
13D/G
|
10%
|
$1,795,528
2,181,422 shares
|
$0 | 30 Sep 2025 |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13D/G
13F
Company
|
10%
|
$1,795,528
2,181,422 shares
|
$0 | 30 Sep 2025 |
| Cormorant Asset Management, LP |
13D/G
|
10%
|
—
3,834,335 shares
|
$0 | 31 Mar 2026 |
| Sirenia Capital Management LP |
13D/G
|
9.9%
|
$25,489,948
11,586,340 shares
|
$0 | 31 Mar 2026 |
| Vestal Point Capital, LP |
13D/G
|
9.9%
|
$3,518,752
4,275,000 shares
|
$0 | 30 Sep 2025 |
| Opaleye Management Inc. |
13D/G
|
7.6%
|
$787,500
750,000 shares
|
$0 | 31 Dec 2024 |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
5.7%
|
—
1,953,467 shares
|
$0 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$98,106.
Buys
$98,106
Insiders: 3
Sells
$0
Insiders: 0
Net
+$98,106
Shares: +51,105
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 51,105
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 51,105 | 0 | $98,106 | $0 | +$98,106 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to iBio, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest current holder
Antonio Bernardino Guimaraes Parada
Net 12M change
+$98,106
Latest report
18 May 2026
Recent insider transactions for iBio, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Elizabeth Stoner | IBIO | Stock Option (right to buy) | Award | 60,000 | 60,000 | 18 May 2026 | Direct | |||
| Marc Banjak | IBIO | Common Stock | Purchase | 125.9% | $23,055 | $1.65 | 13,934 | 25,000 | 26 Mar 2026 | Direct |
| Felipe Duran | IBIO | Common Stock | Purchase | 223% | $50,132 | $2.02 | 24,835 | 35,974 | 19 Mar 2026 | Direct |
| Martin Brenner | IBIO | Common Stock | Purchase | 67.4% | $24,919 | $2.02 | 12,336 | 30,652 | 19 Mar 2026 | Direct |
| Marc Banjak | IBIO | Stock Option (right to buy) | Award | 146,000 | 146,000 | 28 Jan 2026 | Direct | |||
| Felipe Duran | IBIO | Stock Option (right to buy) | Award | 179,000 | 179,000 | 28 Jan 2026 | Direct | |||
| Martin Brenner | IBIO | Stock Option (right to buy) | Award | 479,000 | 479,000 | 28 Jan 2026 | Direct | |||
| Evert B. Schimmelpennink | IBIO | Stock Option (right to buy) | Award | 13,500 | 13,500 | 20 Nov 2025 | Direct | |||
| William D. Clark | IBIO | Stock Option (right to buy) | Award | 13,500 | 13,500 | 20 Nov 2025 | Direct | |||
| Gary Sender | IBIO | Stock Option (right to buy) | Award | 13,500 | 13,500 | 20 Nov 2025 | Direct | |||
| Alexandra Kropotova | IBIO | Stock Option (right to buy) | Award | 13,500 | 13,500 | 20 Nov 2025 | Direct | |||
| Antonio Bernardino Guimaraes Parada | IBIO | Stock Option (right to buy) | Award | 13,500 | 13,500 | 20 Nov 2025 | Direct | |||
| David Arkowitz | IBIO | Stock Option (right to buy) | Award | 13,500 | 13,500 | 20 Nov 2025 | Direct | |||
| Felipe Duran | IBIO | Stock Option (right to buy) | Award | 75,000 | 75,000 | 20 Oct 2025 | Direct | |||
| Marc Banjak | IBIO | Stock Option (right to buy) | Award | 55,000 | 55,000 | 20 Oct 2025 | Direct | |||
| Martin Brenner | IBIO | Stock Option (right to buy) | Award | 180,000 | 180,000 | 20 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.